Trial · NCT00818207
Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
NCT00818207, Phase 4, Completed, Pfizer; results first posted 2012-03-30
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit. Trials, record NCT00818207. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00818207
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
- NCT number
- NCT00818207
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 1,380 participants, actual
- Lead sponsor
- Pfizer
- Conditions
- Smoking Cessation, Insurance Coverage
- Interventions
- Full Smoking Cessation Treatment Coverage (100%), No Smoking Cessation Treatment Coverage (0%)
- First posted
- 2009-01-07
- Last updated
- 2012-03-30
- Results first posted
- 2012-03-30
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants With 7-Day Point Prevalence (PP) of Abstinence | Week 26 | Percentage of participants who self-reported tobacco abstinence for the previous 7 days (7-day PP) with a negative response to the following questions: "Have you smoked any cigarettes (even a puff) in the last 7 days?" and "Have you used any nicotine-containing product (such as chew, snuff, pipe, cigar) other than a Nicotine Replacement Therapy (NRT) (smoking cessation treatment \[SCT\]) in the last 7 days?" |
| Secondary | Percentage of Participants With Biochemically Confirmed 7-Day PP Abstinence From Tobacco | Week 26 | PP tobacco abstinence was adjudicated if the following conditions were met:(a) self-reported tobacco abstinence for the previous 7 days with a negative response to the questions "Have you smoked any cigarettes (even a puff) in the last 7 days?" and "Have you used any nicotine-containing product (such as chew, snuff, pipe, cigar) other than an NRT (SCT) in the last 7 days?" confirmed by negative urine cotinine test results (defined as cotinine levels less than \[\<\]200 nanograms per milliliter \[ng/mL\]). |
| Secondary | Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | Week 26, Week 39, and Week 52 | CA from smoking was adjudicated if the following conditions were met:(a) self-reported continuous tobacco abstinence during the defined time point with a negative response to the questions "Have you smoked any cigarettes (even a puff) since the last contact/visit?" at every visit from Week 26 through Week 52 (Weeks 26, 39, and 52) and "Have you used any nicotine-containing product (such as chew, snuff, pipe, cigar) other than an NRT (SCT) since the last contact/visit?" and (b) urine cotinine test results were neither positive (greater than or equal to \[≥\]200 ng/mL) nor missing. |
| Secondary | Percentage of Participants With 7-Day PP of Abstinence at Week 13 | Week 13 | PP tobacco abstinence was adjudicated if the participant self-reported tobacco abstinence for the previous 7 days with a negative response to the following questions: "Have you smoked any cigarettes (even a puff) in the last 7 days?" and "Have you used any nicotine-containing product (such as chew, snuff, pipe, cigar) other than a NRT (SCT) in the last 7 days?" |
| Secondary | Percentage of Participants With Long Term Quit Rate (LTQR) Through Weeks 26 to 52 | Week 26 to Week 52 | LTQR was adjudicated if the following conditions were met: the participant self-reported tobacco abstinence for the previous 7 days with a negative response to the following questions: "Have you smoked any cigarettes (even a puff) in the last 7 days?" and "Have you used any nicotine-containing product (such as chew, snuff, pipe, cigar) other than a NRT (SCT) in the last 7 days?" and had no more than 6 cumulative days of using nicotine containing products from Weeks 26 to 52 |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Participants With 7-Day Point Prevalence (PP) of Abstinence | Week 26 | Intent to Treat (ITT) Population: all randomized participants | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Biochemically Confirmed 7-Day PP Abstinence From Tobacco | Week 26 | ITT | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | Week 26, Week 39, and Week 52 | ITT | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With 7-Day PP of Abstinence at Week 13 | Week 13 | ITT | Percentage of Participants | NUMBER |
| SECONDARY | Percentage of Participants With Long Term Quit Rate (LTQR) Through Weeks 26 to 52 | Week 26 to Week 52 | ITT | Percentage of Participants | NUMBER |
Source ClinicalTrials.gov
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With 7-Day Point Prevalence (PP) of Abstinence | Reimbursement for Smoking Cessation Therapy (SCT) | 20.8 | Percentage of Participants | ||
| Percentage of Participants With 7-Day Point Prevalence (PP) of Abstinence | No Reimbursement for SCT | 13.9 | Percentage of Participants | ||
| Percentage of Participants With Biochemically Confirmed 7-Day PP Abstinence From Tobacco | Reimbursement for Smoking Cessation Therapy (SCT) | 15.7 | Percentage of Participants | ||
| Percentage of Participants With Biochemically Confirmed 7-Day PP Abstinence From Tobacco | No Reimbursement for SCT | 10.1 | Percentage of Participants | ||
| Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | Reimbursement for Smoking Cessation Therapy (SCT) | Week 26 | 15.7 | Percentage of Participants | |
| Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | No Reimbursement for SCT | Week 26 | 10.1 | Percentage of Participants | |
| Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | Reimbursement for Smoking Cessation Therapy (SCT) | Week 39 | 7.8 | Percentage of Participants | |
| Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | No Reimbursement for SCT | Week 39 | 6.3 | Percentage of Participants | |
| Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | Reimbursement for Smoking Cessation Therapy (SCT) | Week 52 | 6.6 | Percentage of Participants | |
| Percentage of Participants With Continuous Abstinence (CA) at Weeks 26, 39, and 52 | No Reimbursement for SCT | Week 52 | 5.6 | Percentage of Participants |
1 to 10 of 26Source ClinicalTrials.gov
See all 26 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Reimbursement for Smoking Cessation Therapy (SCT) | 696 | |
| Overall Study | STARTED | No Reimbursement for SCT | 684 | |
| Overall Study | COMPLETED | Reimbursement for Smoking Cessation Therapy (SCT) | 474 | |
| Overall Study | COMPLETED | No Reimbursement for SCT | 417 | |
| Overall Study | NOT COMPLETED | Reimbursement for Smoking Cessation Therapy (SCT) | 222 | |
| Overall Study | NOT COMPLETED | No Reimbursement for SCT | 267 |
Source ClinicalTrials.gov
Adverse events166
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Constipation | Gastrointestinal disorders | Reimbursement for Smoking Cessation Therapy (SCT) | 21 | 696 | |
| other | Constipation | Gastrointestinal disorders | No Reimbursement for SCT | 19 | 684 | |
| other | Diarrhoea | Gastrointestinal disorders | Reimbursement for Smoking Cessation Therapy (SCT) | 11 | 696 | |
| other | Diarrhoea | Gastrointestinal disorders | No Reimbursement for SCT | 18 | 684 | |
| other | Dyspepsia | Gastrointestinal disorders | Reimbursement for Smoking Cessation Therapy (SCT) | 14 | 696 | |
| other | Dyspepsia | Gastrointestinal disorders | No Reimbursement for SCT | 7 | 684 | |
| other | Nausea | Gastrointestinal disorders | Reimbursement for Smoking Cessation Therapy (SCT) | 107 | 696 | |
| other | Nausea | Gastrointestinal disorders | No Reimbursement for SCT | 50 | 684 | |
| other | Vomiting | Gastrointestinal disorders | Reimbursement for Smoking Cessation Therapy (SCT) | 17 | 696 | |
| other | Vomiting | Gastrointestinal disorders | No Reimbursement for SCT | 13 | 684 |
1 to 10 of 166Source ClinicalTrials.gov
See all 166 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Reimbursement for Smoking Cessation Therapy (SCT) | ||
| Total, all-cause mortality | No Reimbursement for SCT | ||
| Total, other adverse events | Reimbursement for Smoking Cessation Therapy (SCT) | 335 | 696 |
| Total, other adverse events | No Reimbursement for SCT | 246 | 684 |
| Total, serious adverse events | Reimbursement for Smoking Cessation Therapy (SCT) | 35 | 696 |
| Total, serious adverse events | No Reimbursement for SCT | 25 | 684 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24885542 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Reimbursement for Smoking Cessation Therapy (SCT) vs No Reimbursement for SCT: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00818207
GET https://conductscience.org/api/trials/v1/NCT00818207/results?page=2